Wolfe Research initiated coverage on BeOne Medicines with a new price target
Stocks in this Quantisnow insightHealth Care
Historical context for ONC
Across the 17 sessions after earlier ONC headlines, the stock closed higher 11 times and lower 6 times, with a median move of 1.3% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ONC | SPY |
|---|---|---|---|
| Mar 16, 2026 | BeOne Medicines downgraded by Jefferies with a new price target | +2.0% | +1.0% |
| Feb 26, 2026 | BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership | -8.5% | -0.6% |
| Feb 17, 2026 | BeOne Medicines to Present at Upcoming Investor Conferences | +2.5% | +0.2% |
| Feb 11, 2026 | BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26 | -0.6% | -0.0% |
| Jan 13, 2026 | BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference | +5.1% | -0.2% |
| Jan 6, 2026 | ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA | +0.0% | +0.6% |
Quantisnow market dataNASDAQ
ONC
BeOne Medicines Ltd.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2016
Get push alerts for ONC
Full ONC profile on Quantisnow Follow ONC and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time